MARCIA RADANOVIC
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Passive antiamyloid immunotherapy for Alzheimer's disease(2020) LOUREIRO, Julia C.; PAIS, Marcos V.; STELLA, Florindo; RADANOVIC, Marcia; TEIXEIRA, Antonio Lucio; FORLENZA, Orestes V.; SOUZA, Leonardo Cruz dePurpose of review Antiamyloid therapy of Alzheimer's disease tackles the overproduction and clearance of the amyloid-beta peptide (A beta). Immunotherapeutic compounds were tested in large-scale trials. We revisit the recent literature focusing on randomized-controlled trials (RCT) using monoclonal anti-A beta antibodies. Recent findings Forty-three articles on anti-A beta passive immunotherapy for Alzheimer's disease were published between January 2016 and October 2019 regarding 17 RCTs: 13 phase III trials using the monoclonal antibodies bapineuzumab, solanezumab, gantenerumab, crenezumab, and aducanumab; three phase II with crenezumab and aducanumab; and one phase I trial with BAN2401. Studies resulted largely negative considering the effect of the treatment on primary and secondary outcome variables. The incidence of the most important adverse effect, amyloid-related imaging abnormalities (ARIAs) ranged between 0.2 and 22%, in treatment groups. Primary endpoints were not met in eight trials, and five trials were discontinued prior to completion. Passive immunotherapy RCTs failed to show clinically relevant effects in patients with clinically manifest or prodromal dementia. The high incidence of ARIAs indicates that the risk of adverse events may outweigh the benefits of these interventions. Ongoing studies must determine the benefit of such interventions in preclinical Alzheimer's disease, addressing the effect of antiamyloid immunotherapy in samples of asymptomatic carriers of autosomal-dominant mutations related to early-onset Alzheimer's disease.
- Cognitive impairment in remitted late -life depression is not associated with Alzheimer's disease -related CSF biomarkers(2020) LOUREIRO, Julia C.; STELLA, Florindo; PAIS, Marcos V.; RADANOVIC, Marcia; CANINEU, Paulo R.; JOAQUIM, Helena P. G.; TALIB, Leda L.; FORLENZA, Orestes V.
- Cognitive reserve: an evolving concept(2020) RADANOVIC, Marcia
conferenceObject Semantic Network Assessment in Mild Cognitive Impairment and Alzheimer's Disease(2020) MAZIERO, Maria Paula; BELAN, Ariella Fornachiari; CAMARGO, Marina von Zuben de Arruda; FORLENZA, Orestes Vicente; RADANOVIC, Marcia- Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges(2020) PAIS, Marcos; MARTINEZ, Luana; RIBEIRO, Octavio; LOUREIRO, Julia; FERNANDEZ, Romel; VALIENGO, Leandro; CANINEU, Paulo; STELLA, Florindo; TALIB, Leda; RADANOVIC, Marcia; FORLENZA, Orestes V.The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the ""amyloid cascade"" and the ""continuum of AD,"" discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed.